Drug profile · INN
vibegron
OBGEMSA
vibegron (OBGEMSA) is a beta-3 adrenergic receptor agonist. Route of administration: oral. Current US regulatory status: approved.
Drug details — vibegron
- US status
- approved
- Class
- Genito-urinary system and sex hormones (G04)
- Route
- ORAL
- Patents
- 0
- Programs
- 1
- Data quality
- 0.84
Quick answer
vibegron (OBGEMSA) is a beta-3 adrenergic receptor agonist. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Beta-3 adrenergic receptor agonist
Primary target: Beta-3 adrenergic receptor
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is vibegron?
vibegron (OBGEMSA) is a beta-3 adrenergic receptor agonist. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for vibegron?
OBGEMSA is a marketed brand name for vibegron. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of vibegron?
vibegron has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.